Why Grifols SA - ADR’s (GRFS) Stock Is Down 5.98% (2024)

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Grifols SA - ADR before investing.

In this article, we go over a few key elements for understanding Grifols SA - ADR’s stock price such as:

Before we jump into Grifols SA - ADR’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Want to learn more about Grifols SA - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Grifols SA - ADR.

As of May 29, 2024, 4:00 PM, CST, Grifols SA - ADR’s stock price was $6.92.

Grifols SA - ADR is down 5.98% from its previous closing price of $7.36.

During the last market session, Grifols SA - ADR’s stock traded between $7.18 and $7.50. Currently, there are 683.03 million shares of Grifols SA - ADR stock available for purchase.

Grifols SA - ADR’s price-earnings (P/E) ratio is currently at 75.2, which is high compared to the Pharmaceuticals industry median of 22.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Grifols SA - ADR’s (GRFS) price is currently up 7.62% so far this month.

During the month of May, Grifols SA - ADR’s stock price has reached a high of $7.76 and a low of $6.35.

Over the last year, Grifols SA - ADR has hit prices as high as $12.15 and as low as $5.30. Year to date, Grifols SA - ADR’s stock is down 18.59%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of May 28, 2024,, no analysts have changed their rating of Grifols SA - ADR’s stock over the last month.

Additionally, you'll want to evaluate Grifols SA - ADR’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Grifols SA - ADR’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Grifols SA - ADR’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Grifols SA - ADR (GRFS) by visiting AAII Stock Evaluator.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 28, 2024, Grifols SA - ADR has a weighted four-quarter relative price strength of -11.97%, which translates to a Momentum Score of 28 and is considered to be Weak.

Want to learn more about how Grifols SA - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

As of May 29, 2024, Grifols SA - ADR’s stock price is $6.92, which is down 5.98% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Grifols SA - ADR stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.